Skip to Main Content

Combining Amgen’s KRAS-blocking cancer drug Lumakras with other targeted medicines led to higher rates of side effects without improving tumor responses, according to preliminary results from two clinical trials released Thursday.

Amgen secured U.S. approval of Lumakras in May to treat patients with lung cancer caused by a genetic mutation to the KRAS protein. In the future, combining Lumakras with other targeted drugs may lead to more effective treatments for patients with cancer, but the data revealed Thursday show that goal not yet within reach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment